CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA219962 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA219962.

Normal code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Normal
0

Critical

0%

0

High

0%

1

Routine

100%

0

Low

0%

New this month

—

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: TYLENOL WITH NAPROXEN (NAPROXEN SODIUM, ACETAMINOPHEN) — Type 4 - New Combination

Policy FDA-NDA219962 · Pain Management

Routine

Tylenol with Naproxen (NDA219962) is an oral combination tablet of acetaminophen and naproxen approved under a Type 4 New Combination submission, billing under Medicare Part D as a retail pharmacy dru

View alert

Audit documentation

Building an audit file that includes FDA-NDA219962?

The Tripwire Audit Pack exports 12 months of Pain Management policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Pain Management audit pack — $349One-time purchase · not a subscription